Expertos Invitados





NUEVAS TERAPIAS EN LA ESCLEROSIS MULTIPLE

(especial para SIIC © Derechos reservados)
Las terapias actuales de la esclerosis múltiple son principalmente efectivas como profilaxis en el estadio de recaídas y remisiones de la enfermedad, mientras que las terapias más agresivas que parecen ser beneficiosas en el estadio progresivo tienen sólo un beneficio limitado y una toxicidad importante. El neurólogo general individualiza en la actualidad las recomendaciones de la terapia combinada para una indicación aún no autorizada, a menudo en consulta con un especialista en esclerosis múltiple.
yeh9.jpg Autor:
Ann e. Yeh
Columnista Experto de SIIC
Artículos publicados por Ann e. Yeh
Coautor
Bianca Weinstock-Guttman* 
MD, State University of New York, Buffalo, EE.UU.*
Recepción del artículo
14 de Diciembre, 2006 		Aprobación
7 de Febrero, 2007
Primera edición
21 de Agosto, 2007 		Segunda edición, ampliada y corregida
7 de Junio, 2021

NUEVAS TERAPIAS EN LA ESCLEROSIS MULTIPLE

Resumen
La esclerosis múltiple (EM) es una enfermedad inflamatoria autoinmune caracterizada por desmielinización y pérdida axonal en el sistema nervioso central. Desde la última década se encuentran disponibles nuevas terapias inmunomoduladoras como el interferón beta y el acetato de glatiramer. No obstante, estas terapias son sólo parcialmente efectivas. Existe una necesidad continua de formular estrategias terapéuticas más efectivas para combatir los aspectos crónicos y progresivos de la enfermedad. Dada la compleja fisiopatología subyacente al proceso patológico de la EM, la terapia combinada ofrece un abordaje terapéutico racional. Independientemente de la estrategia terapéutica empleada, la intervención temprana seguirá siendo el factor de mayor importancia.

Palabras clave
esclerosis múltiple, terapias combinadas, interferón, acetato de glatiramer, natalizumab


Artículo completo
(castellano)
Extensión:  +/-13.99 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

New Combination Therapies for Multiple Sclerosis

Abstract
Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by demyelination and axonal loss in the central nervous system. Although new immunomodulatory therapies including interferon beta and glatiramer acetate became available during the last decade these therapies are only partially effective. There is a continuing need to develop more effective treatment strategies to combat the chronic and progressive aspects of the disease. In view of the complex pathophysiology underlying the MS disease process, combination therapy offers a rational therapeutic approach. Regardless of the treatment strategy to be employed, early intervention will remain the most important factor.

Key words
multiple sclerosis, combination therapies, interferon, glatiramer acetate, natalizumab


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurología
Relacionadas: Bioética, Farmacología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 13.99 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Bianca Weinstock-Guttman, The Jacobs Neurological Institute, NY 14203, 100 High Street, Suite E-2, Buffalo, EE.UU.
Bibliografía del artículo
1. Rudick R, Cohen JA, Weinstock-Guttman B, Kinkel R, Ransohoff R. Management of multiple sclerosis. New Engl J Med 337:1604-1611, 1997.
2. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for he pathogenesis of demyelination. Ann Neurol 47:707-17, 2000.
3. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125:1450-61, 2002.
4. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA, The interferons: Biological effects mechanisms of action, and use in multiple sclerosis. Ann Neurol 37:7-15, 1995.
5. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis. Mechanism of action. Neurology 51:682-689, 1998.
6. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 655-661, 1993.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294, 1996.
8. PRISMS (Prevention of Relapses and Disability by Interferon ß-1a subcutaneously in Multiple Sclerosis) study Group. Randomized double-blind placebo-controlled study of interferon ß-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504, 1998.
9. European Study Group on Interferon ß-1b in secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon ß-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497, 1998.
10. Secondary Progressive Efficacy Clinical trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) study Group. Randomized controlled trial of recombinant interferon beta-1a in secondary progressive MS. Clinical results. Neurology 56:1496-1504, 2001.
11. Goodkin DE, the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial (abstract). Late Breaking News. Presented at the 52nd annual meeting of the American Academy of Neurology, San Diego, 2000.
12. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679-87, 2002.
13. Calabresi PA, Stone LA, Bash CN, et al. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 48:1446-8, 1997.
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276, 1995.
15. Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 7:209-19, 2001.
16. Dhib-Jalbut S. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 201:71-7, 2002.
17. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290-7, 2001.
18. Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 22:30-8, 1999.
19. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23, 2003.
20. Vollmer TL, Phillips JT, Goodman AD, et al. An open label safety and drug interaction study of natalizumab (Antegren) in combination with IFN beta in patients with MS. Multiple Sclerosis 10(5):511-520, 2004.
21. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899-910, 2006.
22. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911-23, 2006.
23. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease; N. Engl J Med 353:362-368, 2005.
24. Langer-Gould A, Atlas SW, Green AJ et al. Progressive multifocal encephalopathy in a patient treated with natalizumab. N Engl J Med 353:375-381, 2005.
25. Kleinschmidt-DeMasters BK, Tyler KL, Progressive multifocal leukoencphalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369-374, 2005.
26. Hartung HP, Gonsette R, Konig N, et al, and the MIMS-Study Group, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet 360:2018-2025, 2002.
27. Kita M, Cohen JA, Fox RJ, et al. A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis; 56th Annual Meeting of the American Academy of Neurology; San Francisco, California; Neurology S12.004, 2004.
28. Ledda A, Caocci G, Spinicci G et al. Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia 20(12):2217-2218, 2006.
29. Vicari AM, Ciceri F, Folli F et al. Acute promyelocytic leukemia following mitoxantrone as a single agent for the treatment of multiple sclerosis. Leukemia 12(3) 441-2, 1998.
30. Cattaneo C, Almici C, Porlenghi E et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 17(5):985-6, 2003.
31. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18(6):379-96, 2004.
32. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS; The EVIDENCE Trial. Neurology 359:1453-1460, 2002.
33. Durelli L, Verdun E, Barbero P, et al, Every other day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis; results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet 359:1453-1460, 2002.
34. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first 3 years. Neurology 47:889-894, 1996.
35. The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 56:1628-1636, 2001.
36. Pachner AR. Anti-IFNB antibodies in IFNB-treated MS patients. Neurology 61(suppl 5):S1-S5, 2003.
37. Sorensen PS, Ross C, Clemmesen KM, et al, Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing remitting multiple sclerosis. Lancet 302:1184-1191, 2003.
38. Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 61:185-93, 1995.
39. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 47:127-31, 2000.
40. Zang Y, Hong J, Robinson R, et al. Immune regulatory properties and interactions of Copolymer I and beta-interferon 1a in MS. J Neuroimmunol 144-153, 2003.
41. Lublin F, Cutter G, Elfont R, et al. A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS (abstract). Neurology 56(suppl 3):A148, 2001.
42. Yudkin PL, Ellison GW, Ghezzi A, et al, Overview of azathioprine treatment in multiple sclerosis. Lancet 38:1051-5, 1991.
43. Havrdova E, Zivadinov R, Krasensky J et al. Efficacy results form randomized, double blind, placebo controlled study of intramuscular IFN beta-1°, azathioprine, and corticoseteroid combination therapy in patients with RRMS. Multiple Sclerosis 12:S11, 61, 2006.
44. Calabrese PA, Bash CN, Costello K, et al,. Optimization of the safety and efficacy of interferon beta1b and azathioprine combination therapy in multiple sclerosis. Neurology Abstract PO6.089, 2004.
45. Fernandez O, Guerro M, Mayorga C, et al, Combination therapy with interferon beta-1b and azathioprine in secondary progressive MS. A 2 year pilot study. J Neurol 249:1058-62, 2002.
46. Montanari E, Manneschi L, Pesci I, Merelli E, et al. ASPIRE (Azathioprine Secondary Progressive Interferon treated patients; Randomized Evaluation) study: baseline data from a 2-years double blind, randomized, multicentre, pilot study; ECTRIMS/ACTRIMS Thessaloniki, Greece. Multiple Sclerosis P343, 2005.
47. Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 27(2):80-3, 2004.
48. Vermersch P, Waucquier N, Bourteel H, et al. Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and mycophenylate mofetil (Cellcept): results of a phase II clinical trial. Program and abstracts of the 56th Annual Meeting of the American Academy of Neurology; San Francisco, California. Abstract S29.001), 2004.
49. Gogovska I, Ljapcev R, Interferon beta with mycophenolate mofetil in MS, ECTRIMS/ACTRIMS Thessaloniki, Greece. Multiple Sclerosis 11(Suppl 1)S170:P640, 2005.
50. Goodkin DE, Rudick RA, VanderBrug Medendorp S et al, Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37:30-40, 1995.
51. Goodkin DE, Rudick RA, VanderBrug Medendorp S. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analysis of serial MRIs. Neurology 47:1153-7, 1996.
52. Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58:314-7, 2002.
53. Cohen J, Calabresi PA, Fisher E, et al. Rationale, design, and baseline data for the Avonex Combination Trial; ECTRIMS/ACTRIMS Thessaloniki, Greece. Multiple Sclerosis P588; S155, 2005.
54. Rowe VD, Wang D, John HA, et al. Rescue therapy with high dose intravenous methotrexate in MS patients worsening despite Avonex therapy (abstract). Neurology (Suppl 1):A149-150, 2003.
55. Rowe, Biswas S, Feaster H, Dressman L, Hunter J, Rowe E, Wang D, Moreng G. Bimonthly high-dose intravenous methotrexate in MS patients worsening despite Avonex therapy-follow up and the mechanism of action of MTX in the CNS; ECTRIMS/ACTRIMS Thessaloniki, Greece. Multiple Sclerosis 11; S170:P641, 2005.
56. Durelli L, Cocito D, Riccio A. High dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 36:238-243, 1986.
57. Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: A critical review. J Neurol Sci 160:16-25, 1998.
58. Barnes D, Hughes RAC, Morris R, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349:902-906, 1997.
59. Beck RW, Cleary PA, Trobe J, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329:1764-1769, 1993.
60. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51:239-245, 1998.
61. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57:1239-47, 2001.
62. Salama HH, Kolar OJ, Zang YC, et al. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Multiple Sclerosis 9:28-31, 2003.
63. Goodman A, Rossman H, Bar-Or A, et al; GLANCE: A double blind, randomized placebo-controlled parallel group safety study of natalizumab in combination with glatiramer acetate in subjects with RRMS; AAN, Miami, FL Neurology 64(6):A277:S36.003, 2005.
64. Bielekova B, Reichert-Scrivner S, Wuerfel J, et al. Combination therapy of MS patients with incomplete response to interferon-beta with humanized antibody against the interleukin-2 receptor alpha chain (abstract). Multiple Sclerosis 8(suppl 1):S4, 2002.
65. Rose J, Burns J, Bjorklund J et al. Daclizumab phase I/II trial in RRMS: MRI and clinical results; ECTRIMS/ACTRIMS Thessaloniki, Greece. Multiple Sclerosis 11; S155:P590, 2005.
66. Rosenberg GA. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8:586-95, 2002.
67. Nelissen I, Martens E, Van Den Steen PE, Proost P, et al, Gelatinase B/matrix metalloproteinase-9 cleaves interferon-ß and is a target for immunotherapy. Brain 126:1371-1381, 2003.
68. Paemen L, Martens E, Norga K, et al. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52:105-11, 1996.
69. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration; Minocycline as a potential therapy for multiple sclerosis. Brain 125:1297-1308, 2002.
70. Bashire R, Kirby DL, The safety and tolerability of IFN beta -1a and Minocycline in RRMS; CMSC, Orlando, International MS Care 2005.
71. Metz LM, Li D, Myles ML, Traboulsee A, Duquette P, Yong VW, on behalf of the Canadian MS/MRI Research Group A randomized, double-blind, placebo-controlled, parallel study assessing the add-on effect of minocycline in relapsing-remitting multiple sclerosis subjects treated with glatiramer acetate; ECTRIM/ACTRIM, Thessaloniki, Greece. Multiple Sclerosis 11(S1) S87: P341, 2005.
72. Minagar, Alexander JS, Brooks R, Kelley RE, González Toledo E. An open-label trial of combination therapy with intramuscular interferon beta-1a and oral doxycycline in patients with multiple sclerosis. ECTRIM/ACTRIM, Thessaloniki, Greece. Multiple Sclerosis 11 (S1) P312-S79, 2005.
73. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis; a randomized, three arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 308:173-80, 1983.
74. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43:910-8, 1993.
75. The Canadian Cooperative Multiple Sclerosis Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337:441-6, 1991.
76. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al, Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 3:178-185, 1997.
77. Gobbini MI, Smith ME, Richert ND, et al. Effect of open-label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99:142-149, 1999.
78. Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Guttmann C, Bakshi R, Olek M, Stone L, Stuart D, Orav J, Stuart W, Weiner H. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active MS on interferon. Multiple Sclerosis 11:573-582, 2005.
79. Kaufman M, Norton HJ, Sonnefeld G. A randomized controlled safety trial of IFN beta 1-a and oral cyclophosphamide in MS. Internat J MS Care 4:174-182, 2002.
80. Jeffery DR, Chepuri N, Durden DD, Burdette JH. A pilot trial of combination therapy with mitoxantrone and IFN beta-1b using monthly gadolinium enhanced MRI. Multiple Sclerosis 11(3):296-31, 2005.
81. Vollmer T, Panitch H, Freedman SK et al. Short term induction with mitoxantrone preceding treatment with GA offers early and pronounced effects on MRI disease activity in patients with relapsing forms of MS. Multiple Sclerosis 12(62):S11, 2006.
82. Boggild M. Rationale and experience with combination therapies in multiple sclerosis. J Neurol 253(Suppl 6): VI 45-51, 2006.
83. Stuve O, Prod'homme T, Slavin A, Youssef S, Dunn S, Steinman L, Zamvil SS. Statins and their potential targets in multiple sclerosis therapy. Expert Opin Ther Targets 7:613-22, 2003.
84. Stuve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 16:393-401, 2003.
85. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:39-40, 2002.
86. Kamm C, Mattle H, Greeve I, Tettenborn B, Kappos L, Goebels N, for the SWABIMS Study Group; SWABIMS-SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis; ECTRIM/ACTRIM, Thessaloniki, Greece, Multiple Sclerosis 11(S1);S 156:P591, 2005.
87. Bar-Or a, Jalili F, Niino M, et. al: Antigen-specific immunomodulation in MS patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin; ECTRIM/ACTRIM, Thessaloniki, Greece. Multiple Sclerosis 11(S1); S167:P632, 2005.
88. Stuve O, Youssef S, Weber M et al. Immunomodulatory synergy by combination of atorvastatin and GA in treatment of CNS autoimmunity. J Clin Invest 116(4):1037-44, 2006.
89. Swanborg RH, Whittum-Hudson JA, Hudson AP. Human herpes virus 6 and Chlamydia pneumoniae as etiologic agents in MS - a critical review. Microbes Infect 4:1327-33, 2002.
90. Sriram S, Yi-Yao S, Moses H, et al, A pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS. Neurology 62(suppl); A494, 2004.
91. Friedman JE, Zabriskie JB, Plank C, Ablashi D, et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Multiple Sclerosis 11(3):286-95, 2005.
92. Wade DT, Young CA, Chaudhuri KR, et al. A randomized placebo controlled exploratory study of Vit B12, lofepramine and L-phenylalanine (the "Cari Loder regime") in the treatment of MS. J Neurol Neurosurg Neuropsychiatry 73:246-249, 2002.
93. Puri BK, Bydder GM, Chaudhuri KR et al. MRI changes in MS following treatment with lofepramine and L-phenylalanine. NeuroReport 12:1821-4, 2001.
94. Geffard M, Tranchant C, Fleury M, Wiertlewski S, Guennoc AM, Dabadie MP. GEMSEP1: A new drug candidate for secondary progressive form of multiple sclerosis; ECTRIM/ACTRIM, Thessaloniki, Greece. Multiple Sclerosis 11(S1); S165:P622, 2005.
95. Weinstock-Guttman B, Baier M, Feichter J, et al. A randomized study of low fat diet with omega-3 fatty acids supplementation in patients with RRMS. Prostaglandins, Leukotrienes & Essential Fatty Acids 73:397-404, 2005.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008